TEL AVIV, Israel, Sept. 8, 2010 (GLOBE NEWSWIRE) -- mBeach Software Inc. ("MBHS") (OTCBB:MBHS) announced today plans to redefine the activities of MBHS and Skin Cancer Scanning Ltd. (SCS). This follows the July 15 announcement of the closure of the merger with SCS, as a result of which MBHS holds 100% of SCS.
This new plan defines how each company will focus on its core competence activities, with the goal of maximizing synergies, and creating stronger shareholder value.
Under the new plan, SCS will focus on its core competencies of research and development, regulatory issues, and conducting further clinical trials in Israel. MBHS will focus on worldwide business and marketing activities.
The former management of MBHS has been entirely replaced by a new management, including members of the former SCS management. The new team combines leading scientific and technical experts as well as international marketing experience and expertise.
Col. Yossi Biderman, MBHS's new CEO, stated, "We feel this new restructuring of mBeach and SCS will best leverage the core competencies of each company. This follows our strategy to increase synergies between the companies and grow total shareholder value. We believe this move will strengthen the company and enable us to succeed in the global market for advanced technologies to better detect skin cancers."
About SCS
Skin Cancer Scanning Ltd. (SCS) is a medical device company pioneering the development and commercialization of a revolutionary and proprietary imaging system for the early detection and diagnosis of skin cancer.
Our product, SkinScan 650, is a non-invasive, point-of-care (in the doctor's office) system to detect and identify different kinds of skin nevi, tumors, lesions and cancers. SkinScan 650 enables physicians to diagnose skin cancer at an earlier, more curable stage. This will reduce the number of biopsies, lower treatment costs, and improve quality of life.
For more information on SCS, visit .
Forward Looking Statements
This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of SCS products, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.
CONTACT: mBeach Software Inc. Col. Yossi Biderman, CEO info@scs-med.com
